{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:54:30Z","timestamp":1791096870267,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ijantimicag.2011.12.006","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T13:17:55Z","timestamp":1329225475000},"page":"295-299","source":"Crossref","is-referenced-by-count":133,"title":["Accelerating resistance, inadequate antibacterial drug pipelines and international responses"],"prefix":"10.1016","volume":"39","author":[{"given":"Ursula","family":"Theuretzbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.coph.2011.08.002","article-title":"Update on antibacterial and antifungal drugs\u2014can we master the resistance crisis?","volume":"11","author":"Theuretzbacher","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkr378","article-title":"The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response","volume":"67","author":"Walsh","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","article-title":"Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria","volume":"54","author":"Mauldin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0025","unstructured":"ECDC\/EMEA Joint Technical Report. The bacterial challenge: time to react. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2009. EMEA\/576176\/2009. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0030","doi-asserted-by":"crossref","DOI":"10.2807\/ese.14.45.19393-en","article-title":"Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009","volume":"14","author":"Lepape","year":"2009","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1086\/653203","article-title":"Charting the course for the future of science in healthcare epidemiology: results of a survey of the membership of the Society of Healthcare Epidemiology of America","volume":"31","author":"Sinaii","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0040","series-title":"Proceedings of the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Susceptibility of bacteraemic Pseudomonas aeruginosa: a 55-country analysis from 2004 to 2008","author":"Hoban","year":"2010"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0045","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2010. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC; 2011. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1111_SUR_AMR_data.pdf.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/AAC.01446-09","article-title":"Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0055","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2011.10.004","article-title":"Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options","volume":"39","author":"Kempf","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1469-0691.2010.03262.x","article-title":"Trends among pathogens reported as causing bacteraemia in England, 2004 to 2008","volume":"17","author":"Wilson","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2011.12.006_bib0070","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived","volume":"64","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2011.12.006_bib0075","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0163-4453(09)60004-9","article-title":"Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria","volume":"59","author":"Eliopoulos","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0085","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10096-010-0921-3","article-title":"Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary","volume":"29","author":"Toth","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkr431","article-title":"Emergence of Klebsiella pneumoniae isolate co-producing NDM-1 with KPC-2 from India","volume":"67","author":"Kumarasamy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0095","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/AAC.00987-08","article-title":"First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States","volume":"53","author":"Navon-Venezia","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/MCC.0b013e32834c9d87","article-title":"Recent trends in antibiotic resistance in European ICUs","volume":"17","author":"van Duijn","year":"2011","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0110","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/jac\/dkq191","article-title":"Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination","volume":"65","author":"Perez","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0115","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1086\/652759","article-title":"Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes","volume":"50","author":"Sengstock","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0120","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an Intensive Care Unit","volume":"303","author":"Sanchez Garcia","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1179\/joc.2011.23.2.71","article-title":"Eight-year (2002\u20132009) summary of the linezolid (Zyvox\u00ae Annual Appraisal of Potency and Spectrum; ZAAPS) Program in European Countries","volume":"23","author":"Ross","year":"2011","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10096-009-0823-4","article-title":"Detection of new mutations conferring resistance to linezolid in glycopeptide-intermediate susceptibility Staphylococcus hominis subspecies hominis circulating in an intensive care unit","volume":"29","author":"Sorlozano","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijantimicag.2009.02.005","article-title":"Future antibiotics scenarios: is the tide starting to turn?","volume":"34","author":"Theuretzbacher","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.coph.2011.07.008","article-title":"Resistance drives antibacterial drug development","volume":"11","author":"Theuretzbacher","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0145","article-title":"The crisis of no new antibiotics\u2014what is the way forward?","author":"Piddock","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0155","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2217\/fmb.09.97","article-title":"Antibiotics: derivative drugs, novel compounds and the need for effective resistance strategies","volume":"4","author":"Theuretzbacher","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0160","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1128\/AAC.49.12.4821-4833.2005","article-title":"Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents","volume":"49","author":"Hurdle","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0165","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/JB.01043-10","article-title":"Control of lipopolysaccharide biosynthesis by FtsH-mediated proteolysis of LpxC is conserved in enterobacteria but not in all Gram-negative bacteria","volume":"193","author":"Langklotz","year":"2011","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03702.x","article-title":"Antibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin?","volume":"18","author":"Carlet","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0175","unstructured":"Mossialos E, Morel CM, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. Copenhagen, Denmark: World Health Organization, on behalf of the European Observatory on Health Systems and Policies; 2010. http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0011\/120143\/E94241.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0180","unstructured":"Center for Global Development. When medicines fail: a global push to fight drug resistance. Washington, DC: Center for Global Development; 2010. http:\/\/www.cgdev.org\/section\/initiatives\/_active\/drugresistanceglobalhealth\/about1 [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0185","unstructured":"British Society for Antimicrobial Chemotherapy. Report of the British Society for Antimicrobial Chemotherapy Initiative. The urgent need: regenerating antibacterial drug discovery development. Birmingham, UK: BSAC; 2011. http:\/\/www.bsac.org.uk\/Resources\/BSAC\/TUN%20Report.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0190","doi-asserted-by":"crossref","unstructured":"Infectious Diseases Society of America. The 10\u00d7\u201820 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081\u20133.","DOI":"10.1086\/652237"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0195","unstructured":"ReAct. Collaboration for innovation\u2014the urgent need for new antibiotics; 2011. http:\/\/www.reactgroup.org\/news\/176\/18.html [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0200","doi-asserted-by":"crossref","first-page":"c2071","DOI":"10.1136\/bmj.c2071","article-title":"Tackling antibiotic resistance","volume":"340","author":"So","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0205","unstructured":"European Centre for Disease Prevention and Control. ECDC welcomes EU\/US Transatlantic Taskforce on Antimicrobial Resistance. Stockholm, Sweden: ECDC; 2009. http:\/\/www.ecdc.europa.eu\/en\/press\/news\/Lists\/News\/ECDC_DispForm.aspx?List=32e43ee8-e230-4424-a783-85742124029a&ID=320 [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0210","unstructured":"Transatlantic Taskforce on Antimicrobial Resistance (TATFAR). Recommendations for future collaboration between the U.S. and EU; 2011. http:\/\/www.cdc.gov\/drugresistance\/pdf\/tatfar-report.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0215","unstructured":"European Commission Action plan against the rising threats from antimicrobial resistance. Brussels, Belgium: European Commission; 2011. http:\/\/ec.europa.eu\/dgs\/health_consumer\/docs\/communication_amr_2011_748_en.pdf [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0220","unstructured":"Innovative Medicines Initiative. 5th Call 2012. Tackling resistance. Innovative Medicines Initiative; 2011. http:\/\/www.imi.europa.eu\/content\/5th-call-2012 [accessed 16 January 2012]."},{"key":"10.1016\/j.ijantimicag.2011.12.006_bib0225","unstructured":"European Commission. Commission recommendation of 27 October 2011 on the research Joint Programming Initiative \u2018The microbial challenge\u2014an emerging threat to human health\u2019. European Commission; 2011. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2011:315:0001:0003:EN:PDF [accessed 16 January 2012]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T17:53:20Z","timestamp":1561312400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857912000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0924857912000143"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.12.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}